Skip to main content

Table 2 Trogocytosis capabilities of tumor cells from hematological malignancy patients

From: Trogocytic intercellular membrane exchanges among hematological tumors

  Allogeneic trogocytosis Autologous trogocytosis
  Donor cells Trogocytic cells (%) Donor cells Trogocytic cells (%)
Acceptor cells PKH67 HLA-G1 PKH67
T lymphoma LCL-HLA-G1 57.8 35.5 T lymphoma 55.7
B cell Lymphoma (mantle) 12.6 12.5 B cell lymphoma (mantle) 8.1
B-CLL 15 17.9 9.3 B-CLL 15 23
B-CLL 14 14.7 11.7 B-CLL 14 11.5
B-CLL 13 15 9.1 B-CLL 13 22.2
B-CLL 12 0.8 15.7   
B-CLL 11 2.5 19.1   
B-CLL 10 nt 23.4   
B-CLL 9 nt 30.4   
B-CLL 8 nt 16.7   
B-CLL 7 nt 29   
B-CLL 6 nt 30.1   
B-CLL 5 nt 5   
B-CLL 4 nt 28.5   
B-CLL 3 nt 9.6   
B-CLL 2 nt 7.4   
B-CLL 1 nt 21   
  1. Experiments were performed as described in materials and methods and as exemplified in Figure 2 for patient B-CLL 15. The individual results obtained for each indicated patient are presented. For both allogeneic and autologous trogocytosis experiments, acceptor and donor cells are indicated. The percentage of trogocytic cells is the percentage of acceptor cells that acquired PKH67 and/or HLA-G1 from PKH67hi donor cells. nt not tested.